


Ask a doctor about a prescription for TELMISARTAN HYDROCHLOROTHIAZIDE ALTER 80 mg/12.5 mg TABLETS
Package Leaflet: Information for the Patient
Telmisartan/Hydrochlorothiazide Alter 80 mg/12.5 mg Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Telmisartan/Hydrochlorothiazide Alter is a combination of two active substances, telmisartan and hydrochlorothiazide, in one tablet. Both active substances help to control high blood pressure.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can sometimes lead to a heart attack, heart failure, kidney failure, stroke, or blindness. Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is important to periodically check your blood pressure to ensure it is within the normal range.
Telmisartan/Hydrochlorothiazide is usedfor the treatment of high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled with telmisartan alone.
Do not take Telmisartan/Hydrochlorothiazide Alter
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan/Hydrochlorothiazide Alter.
Warnings and precautions
Consult your doctor before starting to take this medicine if you have or have had any of the following disorders or diseases:
Tell your doctor before taking this medicine:
Your doctor may need to check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take Telmisartan/Hydrochlorothiazide Alter".
Tell your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Telmisartan/Hydrochlorothiazide Alter. Your doctor will decide whether to continue treatment. Do not stop taking Telmisartan/Hydrochlorothiazide Alter on your own.
If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. The use of telmisartan/hydrochlorothiazide is not recommended during pregnancy (first 3 months) and should not be administered after the third month of pregnancy as it may cause serious harm to your baby, see section Pregnancy.
Treatment with hydrochlorothiazide can cause an electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, somnolence, restlessness, pain or muscle cramps, nausea, vomiting, muscle fatigue, and an abnormally fast heart rate (more than 100 beats per minute). If you experience any of these symptoms, tell your doctor.
You should also tell your doctor if you experience increased skin sensitivity to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) that appear more quickly than usual.
If you are going to undergo surgery or anesthesia, tell your doctor that you are taking telmisartan/hydrochlorothiazide.
Telmisartan/hydrochlorothiazide may be less effective in lowering blood pressure in black patients.
Children and adolescents
The use of telmisartan/hydrochlorothiazide is not recommended in children and adolescents up to 18 years of age.
Taking Telmisartan/Hydrochlorothiazide Alter with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Your doctor may need to change the dose of those other medicines or take other precautions. In some cases, it may be necessary to stop taking some of these medicines, especially if you are taking telmisartan/hydrochlorothiazide with any of the following medicines:
Telmisartan/hydrochlorothiazide may increase the ability of other medicines to lower blood pressure or medicines that can potentially lower blood pressure (e.g., baclofen, amifostine).
Additionally, the decrease in blood pressure may be enhanced by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should tell your doctor about the need to adjust the dose of your other medicines while taking telmisartan/hydrochlorothiazide.
The effect of telmisartan/hydrochlorothiazide may be reduced when using non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin or ibuprofen).
Taking Telmisartan/Hydrochlorothiazide Alter with food and alcohol
You can take this medicine with or without food.
Avoid drinking alcohol until you have talked to your doctor. Alcohol may further lower your blood pressure and/or increase the risk of feeling dizzy or weak.
Pregnancy and breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Pregnancy
You should tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking telmisartan/hydrochlorothiazide before you become pregnant or as soon as you find out you are pregnant, and will recommend that you take another blood pressure-lowering medicine instead. The use of telmisartan/hydrochlorothiazide is not recommended during pregnancy and should not be administered after the third month of pregnancy as it may cause serious harm to your baby when administered after that time.
Breastfeeding
Tell your doctor if you are about to start or are breastfeeding, as telmisartan/hydrochlorothiazide is not recommended for use in women during this time. Your doctor may decide to give you a treatment that is more suitable if you want to breastfeed.
Driving and using machines
Some patients feel dizzy or tired when taking telmisartan/hydrochlorothiazide Alter. If you feel dizzy or tired, do not drive or use machines.
Telmisartan/Hydrochlorothiazide Alter contains sorbitol
This medicine contains 42.948 mg of sorbitol in each tablet, equivalent to 56.51 mg/g.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is one tablet per day. Try to take the tablet at the same time each day. You can take telmisartan/hydrochlorothiazide with or without food. The tablets should be swallowed with a little water or other non-alcoholic drink. It is important that you take telmisartan/hydrochlorothiazide every day until your doctor tells you to stop.
If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day.
If you take more Telmisartan/Hydrochlorothiazide Alter than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service: telephone 91 562 04 20, indicating the medicine and the amount taken.
If you accidentally take too many tablets, you may experience symptoms such as low blood pressure and rapid heart rate. Slow heart rate, dizziness, vomiting, and reduced kidney function, including kidney failure, have also been reported. Due to the hydrochlorothiazide component, you may also experience significantly low blood pressure and low potassium levels in the blood, which can lead to nausea, somnolence, and muscle cramps and/or irregular heartbeats associated with the concomitant use of medicines like digitalis or certain antiarrhythmic treatments. Contact your doctor or pharmacist immediately or the emergency department of the nearest hospital.
If you forget to take Telmisartan/Hydrochlorothiazide Alter
If you forget to take your medicine, do not worry. Take the dose as soon as you remember and continue as before. If you do not take your tablet one day, take your normal dose the next day. Do nottake a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some adverse effects can be serious and require immediate medical attention:
If you experience any of the following symptoms, you should visit your doctor immediately:
Sepsis* (frequently called "blood infection"), is a serious infection that involves an inflammatory reaction of the entire body, rapid swelling of the skin and mucous membranes (angioedema), blistering and peeling of the outer layer of the skin (toxic epidermal necrolysis); these adverse effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and visit their doctor immediately. If these adverse effects are not treated, they can be fatal.
An increased incidence of sepsis has been observed with telmisartan alone; however, it cannot be ruled out for telmisartan/hydrochlorothiazide.
Possible Adverse Effects of Telmisartan/Hydrochlorothiazide:
Common Adverse Effects(may affect up to 1 in 10 people):
Dizziness.
Uncommon Adverse Effects(may affect up to 1 in 100 people):
Decrease in potassium levels in the blood, anxiety, fainting (syncope), tingling sensation, numbness (paresthesia), dizziness (vertigo), rapid heartbeat (tachycardia), heart rhythm disturbances, low blood pressure, sudden drop in blood pressure when standing up, shortness of breath (dyspnea), diarrhea, dry mouth, flatulence, back pain, muscle spasms, muscle pain, erectile dysfunction (inability to have or maintain an erection), chest pain, and increased uric acid levels in the blood.
Rare Adverse Effects(may affect up to 1 in 1,000 people):
Lung inflammation (bronchitis), activation or worsening of systemic lupus erythematosus (a disease in which the body's immune system attacks the body, causing joint pain, skin rashes, and fever), sore throat, sinus inflammation, feeling of sadness (depression), difficulty falling asleep (insomnia), vision disturbances, breathing difficulties, abdominal pain, constipation, abdominal distension (dyspepsia), general malaise (vomiting), stomach inflammation (gastritis), liver function disorders (Japanese patients show a greater tendency to experience this adverse effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia), and pain in the limbs, muscle cramps, pseudo-influenza syndrome, pain, low sodium levels, increased creatinine, liver enzymes, or creatine phosphokinase levels in the blood.
Adverse reactions reported for one of the individual components may be potential adverse reactions of telmisartan/hydrochlorothiazide, even if they have not been observed in clinical trials with this product.
Telmisartan
The following additional adverse effects have been described in patients taking telmisartan alone:
Uncommon Adverse Effects(may affect up to 1 in 100 people):
Upper respiratory tract infection (e.g., sore throat, sinus inflammation, common cold), urinary tract infections, red blood cell deficiency (anemia), high potassium levels, slow heart rate (bradycardia), kidney function disorders, including acute renal failure, weakness, cough.
Rare Adverse Effects(may affect up to 1 in 1,000 people):
Low platelet count (thrombocytopenia), increased white blood cell count (eosinophilia), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions, drug rash), low blood sugar levels (in diabetic patients), stomach upset, eczema (a skin disorder), osteoarthritis, tendon inflammation, decreased hemoglobin (a blood protein), drowsiness.
Very Rare Adverse Effects(may affect up to 1 in 10,000 people):
Progressive lung tissue fibrosis (interstitial lung disease) **
** Cases of progressive lung tissue fibrosis have been reported during telmisartan treatment. However, it is unknown whether telmisartan was the cause.
Unknown Frequency(cannot be estimated from available data):
Intestinal angioedema: inflammation in the intestine with symptoms such as abdominal pain, nausea, vomiting, and diarrhea has been reported after using similar products.
Hydrochlorothiazide
The following additional adverse effects have been described in patients taking hydrochlorothiazide alone:
Common adverse effects (may affect up to 1 in 10 people):
Nausea, low magnesium levels in the blood.
Rare adverse effects (may affect up to 1 in 1,000 people):
Decreased platelet count in the blood, which increases the risk of bleeding and bruising (small purple-red marks on the skin or other tissues caused by bleeding), high calcium levels in the blood, headache.
Very rare adverse effects (may affect up to 1 in 10,000 people):
Increased pH (acid-base imbalance) due to low chloride levels in the blood, acute respiratory distress (signs include severe breathing difficulties, fever, weakness, and confusion).
Adverse Effects of Unknown Frequency(cannot be estimated from available data):
Skin and lip cancer (non-melanoma skin cancer), salivary gland inflammation, decreased blood cell count (including low red and white blood cell count), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions), decreased or lost appetite, restlessness, dizziness, blurred or yellowish vision, decreased vision, and eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), blood vessel inflammation (necrotizing vasculitis), pancreatitis, stomach upset, yellowing of the skin or eyes (jaundice), pseudo-lupus syndrome (a condition that mimics systemic lupus erythematosus, in which the body's immune system attacks the body), skin disorders such as blood vessel inflammation of the skin, increased sensitivity to sunlight, skin rash, redness of the skin, blistering of the lips, eyes, or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or dysfunction, glucose in the urine (glucosuria), fever, electrolyte imbalance, high cholesterol levels in the blood, decreased blood volume, increased glucose levels in the blood/urine in patients with diagnosed diabetes mellitus, or fat in the blood.
Reporting Adverse Effects:
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date shown on the blister pack and carton after "EXP". The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the SIGRE collection point at your pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Telmisartan/Hydrochlorothiazide Alter
Appearance of the Product and Package Contents
Reddish-colored tablets with white speckles, oblong, without scoring.
Telmisartan/Hydrochlorothiazide Alter is available in blister packs containing 28 tablets.
Marketing Authorization Holder and Manufacturer
Laboratorios Alter, S.A.
Mateo Inurria, 30
28036 Madrid
Spain
Date of the Last Revision of this Leaflet: February 2025.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of TELMISARTAN HYDROCHLOROTHIAZIDE ALTER 80 mg/12.5 mg TABLETS in November, 2025 is around 19.36 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TELMISARTAN HYDROCHLOROTHIAZIDE ALTER 80 mg/12.5 mg TABLETS – subject to medical assessment and local rules.